Back to News
Market Impact: 0.4
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Kiniksa Pharmaceuticals raised its full-year 2026 revenue guidance after ARCALYST revenue grew 58% year over year in the third quarter. The company cited expanding use for recurrent pericarditis and continued clinical pipeline progress; the article did not specify the revised guidance figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
KNSA0.75
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Tech's relief rally extends as attention turns to tough decisions for the Fed
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios